Get the Stockscreener App
3.00
1.69%
0.05
After Hours:
2.95
-0.05
-1.67%
Entera Bio Ltd stock is traded at $3.00, with a volume of 603.19K.
It is up +1.69% in the last 24 hours and up +4.53% over the past month.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
See More
Previous Close:
$2.95
Open:
$2.95
24h Volume:
603.19K
Relative Volume:
0.24
Market Cap:
$519.43M
Revenue:
$42,000
Net Income/Loss:
$-12.38M
P/E Ratio:
-11.39
EPS:
-0.2634
Net Cash Flow:
$-9.61M
1W Performance:
-0.99%
1M Performance:
+4.53%
6M Performance:
+130.77%
1Y Performance:
+38.89%
1-Day Range:
$2.88
$3.15
1-Week Range:
$2.80
$3.15
52-Week Range:
$0.91
$4.20
Entera Bio Ltd Stock (ENTX) Company Profile
Name
Entera Bio Ltd
Sector
Industry
Phone
972-2-532-7151
Address
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
3.00 | 557.52M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-22-21 | Initiated | Aegis Capital | Buy |
Entera Bio Ltd Stock (ENTX) Latest News
Entera Bio Stock Price Forecast. Should You Buy ENTX? - StockInvest.us
Entera Bio Ltd. WarrantADR (ENTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Entera Bio Ltd. SEC Filing (Aug 31, 2026) - Stock Titan
Correction: Entera to Participate in Upcoming Fall Investor Conferences - GlobeNewswire
Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1%Here's Why - MarketBeat
Entera Bio CEO Miranda Toledano to speak at Canaccord Genuity conference - scanx.trade
Entera (ENTX) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Reported Period - vinanet.vn
Entera (ENTX) Results Review: EPS Misses Its Estimate; Market Move: Shares Finish 4.84% Up in the Current Update - vinanet.vn
Entera Bio appoints new chief medical officer - The Globe and Mail
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Entera Bio appoints Riccardo Camisasca as chief medical officer - Investing.com
Entera Bio Names New Chief Medical Officer Ahead of EB613 Phase 3 Start - Minichart
Form 8K Entera Bio Ltd. For: 18 August - Investing.com India
Form 8K Entera Bio Ltd. For: 18 August By Investing.com - Investing.com Nigeria
Entera Bio appoints Riccardo Camisasca as chief medical officer By Investing.com - Investing.com Canada
A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial - Stock Titan
Renaissance Technologies LLC Buys 365,441 Shares of Entera Bio Ltd. $ENTX - MarketBeat
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo - GlobeNewswire
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement - MarketBeat
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7% - MarketBeat
Entera Bio at Canaccord Genuity: oral osteoporosis push advances By Investing.com - Investing.com Canada
Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants - Stock Titan
Entera Bio shares slip as Q2 loss comes in wider than expected - Yahoo Finance
Entera Bio misses Q2 estimates, reports wider loss By Investing.com - Investing.com Nigeria
Entera Bio misses Q2 estimates, reports wider loss - Investing.com
Entera Bio (ENTX) Holds Near $2.86 as Shares Consolidate Between Support and ResistanceZigzag Correction - dars.gov.et
Entera Bio Ltd. (ENTX) stock price, news, quote and history - au.finance.yahoo.com
Entera Bio (NASDAQ:ENTX) Upgraded to Sell at Wall Street Zen - MarketBeat
Entera Bio raises $275M in oversubscribed placement, shares rebound on funding news - scanx.trade
Entera Bio (NASDAQ:ENTX) Announces Earnings Results - MarketBeat
Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million - scanx.trade
Entera Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Entera Bio Reports Q2 2026 Loss and $275 Million Private Placement - Moomoo
Entera Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Entera Bio (ENTX) awards 180,000 options to Chief of R&D - Stock Titan
Entera Q2 2026 earnings: Phase 3 preparation widened the loss - TradingKey
ENTX: FDA-aligned Phase 3 for EB613 and $275M financing secure pipeline progress and cash runway - TradingView
Entera Bio Ltd. Q2 2026: Revenue $0M, Net loss $7.31M, EPS ($0.14) — 10-Q Summary - TradingView
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Entera Bio Sees Funding Sufficient Into 2030 >ENTX - Moomoo
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entera Bio data selected for ASBMR plenary session - PharmaTimes
ENTX Q2'26 Earnings: EPS estimate is (0.08) USD - TradingView
Entera Bio (ENTX): Longitude entities report 4.6% ownership, Seven Fleet 4.1% - Stock Titan
Entera Bio (NASDAQ:ENTX) Trading Down 2.1%Here's What Happened - MarketBeat
BVF Partners Wins Board Designation Rights at Entera Bio with 9.99% Stake - TradingView
Seven Fleet funds disclose 4.1% Entera Bio (ENTX) stake and shared voting power - stocktitan.net
Entera Bio (ENTX) sees BVF build 9.99% stake after $275M financing - Stock Titan
Entera Bio (ENTX) stake of 12.25M shares reported by TCG Crossover - stocktitan.net
Entera Bio Ltd Stock (ENTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):